Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNM Immunome Inc.

Trading 12-19 13:23:00 EST

11.02

-0.09

-0.81%

High11.42	Low10.86	Vol496.07K
Open11.26	D1 Closing11.11	Amplitude5.04%
Mkt Cap687.83M	Tradable Cap498.57M	Total Shares62.42M
T/O5.48M	T/O Rate1.10%	Tradable Shares45.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMNM","market":"US","secType":"STK","nameCN":"Immunome Inc.","latestPrice":11.02,"timestamp":1734632572617,"preClose":11.11,"halted":0,"volume":496071,"delay":0,"floatShares":45242450,"shares":62416845,"eps":-5.693849,"marketStatus":"Trading","change":-0.09,"latestTime":"12-19 13:23:00 EST","open":11.26,"high":11.42,"low":10.86,"amount":5479611.179562001,"amplitude":0.050405,"askPrice":11.02,"askSize":366,"bidPrice":11,"bidSize":626,"shortable":0,"etf":0,"ttmEps":-5.693849,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734642000000},"marketStatusCode":2,"adr":0,"listingDate":1601611200000,"exchange":"NASDAQ","adjPreClose":11.11,"preHourTrading":{"tag":"盘前","latestPrice":11.46,"preClose":11.11,"latestTime":"09:27 EST","volume":1118,"amount":12867.330320000001,"timestamp":1734618446275},"postHourTrading":{"tag":"盘后","latestPrice":11.1099,"preClose":11.11,"latestTime":"19:55 EST","volume":5534,"amount":61526.3819,"timestamp":1734569721468},"volumeRatio":1.132752,"impliedVol":0.8463,"impliedVolPercentile":0.4286},"requestUrl":"/m/hq/s/IMNM","defaultTab":"news","newsList":[{"id":"2489143140","title":"Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2489143140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489143140?lang=en_us&edition=fundamental","pubTime":"2024-12-05 19:01","pubTimestamp":1733396460,"startTime":"0","endTime":"0","summary":"Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/05/2992165/0/en/Nkarta-Announces-IND-Clearance-of-Investigator-Sponsored-Trial-in-Myasthenia-Gravis-and-Opening-of-Enrollment-for-Ntrust-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","IE0031619046.USD","IE00B7SZL793.SGD","BK4022","MG","BK4139","BK4546","BK4161","IMNM","SLE","IE00B19Z4B17.USD","DM","BK4563","IE00B66KJ199.SGD","UCI","CAR","BK4123","BK4230","BK4505","BK4077"],"gpt_icon":0},{"id":"2488987115","title":"BRIEF-Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488987115","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488987115?lang=en_us&edition=fundamental","pubTime":"2024-12-03 07:27","pubTimestamp":1733182041,"startTime":"0","endTime":"0","summary":"BRIEF-Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Dec 2 (Reuters) - Immunome Inc IMNM.O:IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw6dHBs9aFurther company coverage: IMNM.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUAMTSL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","BK4588","IE00BKPKM429.USD","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4563","NDAQ","BK4112","BK4585","BK4139"],"gpt_icon":0},{"id":"2488871959","title":"Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488871959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488871959?lang=en_us&edition=fundamental","pubTime":"2024-12-03 07:26","pubTimestamp":1733181960,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUAMTSL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","LU2210150020.SGD","LU2095319765.USD","IMNM","BK4112","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU2210149790.SGD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585"],"gpt_icon":0},{"id":"2488294957","title":"Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2488294957","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488294957?lang=en_us&edition=fundamental","pubTime":"2024-12-03 07:26","pubTimestamp":1733181960,"startTime":"0","endTime":"0","summary":"BOTHELL, Wash., December 02, 2024----Immunome, Inc.  , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company’s Board of Directors  granted inducement awards consisting of non-statutory stock options to purchase 210,500 shares of common stock to 15 new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635.Each stock option has an exercise price per share equal to $14.08 per share, the Company’s closing sales price on December 2, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued servi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8t6mItN.k.pk_Onr.yBeaA--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6e9f3a3d59001134e813d550d4119c29","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8t6mItN.k.pk_Onr.yBeaA--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6e9f3a3d59001134e813d550d4119c29"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-reports-inducement-grants-under-232600368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","BK4563","TQQQ","IMNM","SQQQ","LU2095319765.USD","LU2210149790.SGD","NDAQ","BK4588","NQmain","IE00B3QW5Z07.USD","IE00B64PRP62.GBP",".IXIC","IE00BKPKM429.USD","BK4112","BK4585","MNQmain","QID","PSQ","QLD"],"gpt_icon":1},{"id":"2486676829","title":"Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486676829","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486676829?lang=en_us&edition=fundamental","pubTime":"2024-11-27 21:00","pubTimestamp":1732712400,"startTime":"0","endTime":"0","summary":"BOTHELL, Wash., November 27, 2024----Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome’s management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time.Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FiM_PWipIlHKq1jeMQ7CNw--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b8b99617c0e053a0a47eee41a432eef5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FiM_PWipIlHKq1jeMQ7CNw--~B/aD0zMzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b8b99617c0e053a0a47eee41a432eef5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-present-piper-sandler-36th-130000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4137","HCSG","BK4563","IMNM"],"gpt_icon":0},{"id":"2485521755","title":"Immunome Files Prospectus for Stock Offering By Selling Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2485521755","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485521755?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:52","pubTimestamp":1732312326,"startTime":"0","endTime":"0","summary":"Immunome (IMNM) filed a prospectus late Friday for the sale of 1.8 million shares by selling shareholders from time to time.The shares covered in the prospectus were issued under the stock issuance ag","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IMNM","BK4563"],"gpt_icon":0},{"id":"2485946214","title":"Immunome files to sell 1.80M shares of common stocks by selling shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2485946214","media":"seekingalpha","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485946214?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:18","pubTimestamp":1732310324,"startTime":"0","endTime":"0","summary":"Immunome (NASDAQ:IMNM) files a prospectus related to offer and resale of about 1.80M shares of common stock.\nThe company will not receive any proceeds from the sale of ordinary shares by the selling shareholder.\nFiling","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4323428-immunome-files-to-sell-180m-shares-of-common-stocks-by-selling-shareholders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2485021414","title":"Immunome files to sell 1.8M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2485021414","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485021414?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:10","pubTimestamp":1732309838,"startTime":"0","endTime":"0","summary":"16:05 EST Immunome (IMNM) files to sell 1.8M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mark...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-files-to-sell-1-8m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-files-to-sell-1-8m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2485211752","title":"BRIEF-Immunome Inc Files For Resale Of Up To 1.8 Million Shares By The Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2485211752","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485211752?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:05","pubTimestamp":1732309531,"startTime":"0","endTime":"0","summary":"Nov 22 (Reuters) - Immunome Inc   :   * IMMUNOME INC FILES FOR RESALE OF UP TO 1.8 MILLION SHARES BY THE SELLING STOCKHOLDER - SEC FILINGSource text: [ Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4008","IMNM","UP"],"gpt_icon":0},{"id":"2485114952","title":"Immunome Inc Files for Resale of up to 1.8 Mln Shares by the Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2485114952","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485114952?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:02","pubTimestamp":1732309371,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nFWN3MT117:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2484156546","title":"argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies","url":"https://stock-news.laohu8.com/highlight/detail?id=2484156546","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484156546?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:00","pubTimestamp":1732082400,"startTime":"0","endTime":"0","summary":"Phase 2 data establish proof-of-concept of efgartigimod SC in myositis. Enrollment to continue in Phase 3 across all three subtypes  under evaluation in ALKIVIA. Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options. Amsterdam, the Netherlands – argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous   in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies , following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy , anti-synthetase syndrome , and dermatomyositis .The ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UwwYml_EjOny.4NgkSZwUA--~B/aD0yMzk7dz03NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/73efc31ede936fb04b960263820794be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UwwYml_EjOny.4NgkSZwUA--~B/aD0yMzk7dz03NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/73efc31ede936fb04b960263820794be"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-advances-clinical-development-efgartigimod-060000807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ARGX","IMNM","BK4161","ARGNF","BK4156","BK4563","DM","BK4546"],"gpt_icon":0},{"id":"2484659948","title":"Immunome (IMNM) Receives a Buy from J.P. Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2484659948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484659948?lang=en_us&edition=fundamental","pubTime":"2024-11-19 20:08","pubTimestamp":1732018126,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Buy rating on Immunome (IMNM – Research Report) on November 15 and set a price target of $23.00. The c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunome-imnm-receives-a-buy-from-j-p-morgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunome-imnm-receives-a-buy-from-j-p-morgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106261372.USD","BK4516","LU2357305700.SGD","BK4504","LU0320765646.SGD","LU0106831901.USD","BK4585","LU1720051108.HKD","LU1074936037.SGD","LU1363072403.SGD","LU1989772840.SGD","LU0314104364.USD","IMNM","LU1720051017.SGD","LU0225283273.USD","BK4534","BK4581","LU1668664300.SGD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU0971096721.USD","BK4563","LU1989772923.USD","BK4139","BK4127","LU0006306889.USD","LU0098860793.USD","IE00BKVL7J92.USD","BK4588","LU1162221912.USD","LU1548497426.USD"],"gpt_icon":0},{"id":"2484626188","title":"Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626188","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484626188?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event –。– All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period –。– Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional nave B cell repopulation as early as eight weeks in the first two patients –。– 40 U.S. clinical sites actively recruiting across the RESET clinical development program, with 16 patients enrolled and 10 patients dosed with CABA-201 as of November 12, 2024 –","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-presents-positive-clinical-120000795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","CRS","BK4110","IE00B66KJ199.SGD","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IMNM","IE0031619046.USD","BK4077","CABA","SLE","BK4139","ACR","BK4546","BK4006","DM","BK4563"],"gpt_icon":1},{"id":"2483322526","title":"Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322526","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483322526?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:28","pubTimestamp":1731670120,"startTime":"0","endTime":"0","summary":"NasdaqCM:IMNM Earnings and Revenue History November 15th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 30%. Earnings per share  missed analyst estimates by 37%.Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US.The company's shares are down 11% from a week ago.We don't want to rain on the parade too much, but we did also find 2 warning signs for Immunome that you need to be mindful of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-third-quarter-2024-earnings-112840707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNM"],"gpt_icon":0},{"id":"2483874899","title":"Immunome Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2483874899","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483874899?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:35","pubTimestamp":1731587700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 07:35 ET (12:35 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2483176178","title":"Immunome Inc :  Piper Sandler Cuts Target Price to $21 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2483176178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483176178?lang=en_us&edition=fundamental","pubTime":"2024-11-14 14:46","pubTimestamp":1731566772,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML05V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNM","BK4563"],"gpt_icon":0},{"id":"2483089750","title":"Immunome Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483089750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483089750?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:19","pubTimestamp":1731557991,"startTime":"0","endTime":"0","summary":"Immunome Inc reports results for the quarter ended September 30 - Earnings SummaryImmunome Inc IMNM.OQ reported a quarterly adjusted loss of 67 cents per share for the quarter ended September 30.  The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nL8N3ML0CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2483897475","title":"Immunome, Inc. Reports Q3 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483897475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483897475?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:19","pubTimestamp":1731557951,"startTime":"0","endTime":"0","summary":"Immunome, Inc. ( ($IMNM) ) has released its Q3 earnings. Here is a breakdown of the information Immunome, Inc. presented to its investors. Immunome...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunome-inc-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunome-inc-reports-q3-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2483860806","title":"Promising Growth Potential for Immunome: Buy Rating Backed by Strategic Acquisitions and Innovative Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483860806","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483860806?lang=en_us&edition=fundamental","pubTime":"2024-11-14 09:15","pubTimestamp":1731546912,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on IMNM stock, giving a Buy rating on November 7. Tyler Van Buren has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-growth-potential-for-immunome-buy-rating-backed-by-strategic-acquisitions-and-innovative-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-growth-potential-for-immunome-buy-rating-backed-by-strategic-acquisitions-and-innovative-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM"],"gpt_icon":0},{"id":"2483867857","title":"Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483867857","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483867857?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:15","pubTimestamp":1731536107,"startTime":"0","endTime":"0","summary":"Immunome, Inc.  came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -30%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.49, delivering a surprise of -28.95%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Immunome , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2.91 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 19.05%. This compares to year-ago revenues of $3.57 million. The company has topped consensus revenue estimates just once over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performan","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunome-inc-imnm-reports-q3-221507159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMNM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunome.com","stockEarnings":[{"period":"1week","weight":-0.2087},{"period":"1month","weight":0.1775},{"period":"3month","weight":-0.2734},{"period":"6month","weight":-0.1069},{"period":"1year","weight":0.3665},{"period":"ytd","weight":0.0383}],"compareEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.0032},{"period":"3month","weight":0.0268},{"period":"6month","weight":0.0767},{"period":"1year","weight":0.2347},{"period":"ytd","weight":0.2335}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.533663},{"month":2,"riseRate":0.5,"avgChangeRate":0.44569},{"month":3,"riseRate":0.5,"avgChangeRate":-0.042263},{"month":4,"riseRate":0,"avgChangeRate":-0.256118},{"month":5,"riseRate":0.75,"avgChangeRate":-0.00531},{"month":6,"riseRate":0.25,"avgChangeRate":-0.0071},{"month":7,"riseRate":0.5,"avgChangeRate":0.081647},{"month":8,"riseRate":0.25,"avgChangeRate":0.057093},{"month":9,"riseRate":0.5,"avgChangeRate":0.191692},{"month":10,"riseRate":0.25,"avgChangeRate":-0.054239},{"month":11,"riseRate":0.2,"avgChangeRate":-0.036745},{"month":12,"riseRate":0.2,"avgChangeRate":-0.137317}],"exchange":"NASDAQ","name":"Immunome Inc.","nameEN":"Immunome Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunome Inc.,IMNM,Immunome Inc.股票,Immunome Inc.股票老虎,Immunome Inc.股票老虎国际,Immunome Inc.行情,Immunome Inc.股票行情,Immunome Inc.股价,Immunome Inc.股市,Immunome Inc.股票价格,Immunome Inc.股票交易,Immunome Inc.股票购买,Immunome Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}